Search Results - "Cutsem, E. Van"

Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Van Cutsem, E, Cervantes, A, Nordlinger, B, Arnold, D

Get full text

Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel by Nordlinger, B., Van Cutsem, E., Gruenberger, T., Glimelius, B., Poston, G., Rougier, P., Sobrero, A., Ychou, M.

“…The past 5 years have seen the clear recognition that the administration of chemotherapy to patients with initially unresectable colorectal liver metastases…”
Get full text

Regorafenib-associated hand–foot skin reaction: practical advice on diagnosis, prevention, and management by McLellan, B., Ciardiello, F., Lacouture, M.E., Segaert, S., Van Cutsem, E.

“…Regorafenib is an orally available, small-molecule multikinase inhibitor with international marketing authorizations for use in colorectal cancer and…”
Get full text

Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies by Taieb, J., Shi, Q., Pederson, L., Alberts, S., Wolmark, N., Van Cutsem, E., de Gramont, A., Kerr, R., Grothey, A., Lonardi, S., Yoshino, T., Yothers, G., Sinicrope, F.A., Zaanan, A., André, T.

“…Microsatellite instable/deficient mismatch repair (MSI/dMMR) metastatic colorectal cancers have been reported to have a poor prognosis. Frequent co-occurrence…”
Get full text

Advanced colorectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up by Van Cutsem, E., Oliveira, J.

Get full text

Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013 by Papamichael, D., Audisio, R.A., Glimelius, B., de Gramont, A., Glynne-Jones, R., Haller, D., Köhne, C.-H., Rostoft, S., Lemmens, V., Mitry, E., Rutten, H., Sargent, D., Sastre, J., Seymour, M., Starling, N., Van Cutsem, E., Aapro, M.

“…Clinicians managing colorectal cancer patients need to appreciate that more than 60% of their patients are >70 years of age, and that these proportions may…”
Get full text

Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study by Kelley, R.K., Verslype, C., Cohn, A.L., Yang, T.-S., Su, W.-C., Burris, H., Braiteh, F., Vogelzang, N., Spira, A., Foster, P., Lee, Y., Van Cutsem, E.

“…Cabozantinib, an orally bioavailable inhibitor of tyrosine kinases including MET, AXL, and VEGF receptors, was assessed in patients with hepatocellular…”
Get full text

Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study by Faivre, S., Niccoli, P., Castellano, D., Valle, J.W., Hammel, P., Raoul, J.-L., Vinik, A., Van Cutsem, E., Bang, Y.-J., Lee, S.-H., Borbath, I., Lombard-Bohas, C., Metrakos, P., Smith, D., Chen, J.-S., Ruszniewski, P., Seitz, J.-F., Patyna, S., Lu, D.R., Ishak, K.J., Raymond, E.

“…In a phase III trial in patients with advanced, well-differentiated, progressive pancreatic neuroendocrine tumors, sunitinib 37.5 mg/day improved…”
Get full text

Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer by Siena, S., Sartore-Bianchi, A., Garcia-Carbonero, R., Karthaus, M., Smith, D., Tabernero, J., Van Cutsem, E., Guan, X., Boedigheimer, M., Ang, A., Twomey, B., Bach, B.A., Jung, A.S., Bardelli, A.

“…Mutations in rat sarcoma (RAS) genes may be a mechanism of secondary resistance in epidermal growth factor receptor inhibitor-treated patients. Tumor-tissue…”
Get full text

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab by De Roock, W., Piessevaux, H., De Schutter, J., Janssens, M., De Hertogh, G., Personeni, N., Biesmans, B., Van Laethem, J.-L., Peeters, M., Humblet, Y., Van Cutsem, E., Tejpar, S.

“…KRAS mutation status is a candidate marker for predicting survival in patients with metastatic colorectal cancer (mCRC) treated with cetuximab (CTX). We…”
Get full text

Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer by Peeters, M., Price, T.J., Cervantes, A., Sobrero, A.F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., Punt, C.J.A., Strickland, A.H., Wilson, G., Ciuleanu, T.E., Roman, L., Van Cutsem, E., Tian, Y., Sidhu, R.

“…The study 20050181 demonstrated significant improvements in progression-free survival (PFS), objective response, and a nonsignificant trend toward increased…”
Get full text

Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials by Taieb, J., Sinicrope, F.A., Pederson, L., Lonardi, S., Alberts, S.R., George, T.J., Yothers, G., Van Cutsem, E., Saltz, L., Ogino, S., Kerr, R., Yoshino, T., Goldberg, R.M., André, T., Laurent-Puig, P., Shi, Q.

“…The prognostic value of KRAS and BRAFV600E mutations in stage III colon cancer (CC) remains controversial and has never been clearly analyzed in patients with…”
Get full text

Primary colon cancer: ESMO Clinical Recommendations for diagnosis, adjuvant treatment and follow-up by Van Cutsem, E., Oliveira, J.

Get full text

Treatment of the elderly colorectal cancer patient: SIOG expert recommendations by Papamichael, D., Audisio, R., Horiot, J.-C., Glimelius, B., Sastre, J., Mitry, E., Van Cutsem, E., Gosney, M., Köhne, C.-H., Aapro, M.

“…Colorectal cancer (CRC) is one of the commonest malignancies of Western countries, with approximately half the incidence occurring in patients >70 years of…”
Get full text

First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study by Van Cutsem, E., Danielewicz, I., Saunders, M. P., Pfeiffer, P., Argilés, G., Borg, C., Glynne-Jones, R., Punt, C. J. A., Van de Wouw, A. J., Fedyanin, M., Stroyakovskiy, D., Kroening, H., Garcia-Alfonso, P., Wasan, H., Falcone, A., Fougeray, R., Egorov, A., Amellal, N., Moiseyenko, V.

“…Background Therapeutic options are limited in patients with unresectable metastatic colorectal cancer (mCRC) ineligible for intensive chemotherapy. The use of…”
Get full text

Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Seufferlein, T, Bachet, J B, Van Cutsem, E, Rougier, P

Get full text

Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials by VAN CUTSEM, E, HOFF, P. M, MARSHALL, J. L, MITCHELL, E. P, PEREZ-MANGA, G, ROUGIER, P, SCHMIEGEL, W, SCHOELMERICH, J, SOBRERO, A, SCHILSKY, R. L, HARPER, P, BUKOWSKI, R. M, CUNNINGHAM, D, DUFOUR, P, GRAEVEN, U, LOKICH, J, MADAJEWICZ, S, MAROUN, J. A

“…This study evaluates the efficacy of capecitabine using data from a large, well-characterised population of patients with metastatic colorectal cancer (mCRC)…”
Get full text

HIPEC in T4a colon cancer: a defendable treatment to improve oncologic outcome? by Hompes, D., Tiek, J., Wolthuis, A., Fieuws, S., Penninckx, F., Van Cutsem, E., D'Hoore, A.

“…Adequate estimation of the potential benefits of ‘adjuvant’ hyperthermia and intraperitoneal chemotherapy (HIPEC) in T4 patients through assessment of the…”
Get full text

Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer by VAN CUTSEM, E, VAN DE VELDE, H, SAFRAN, H, HUMBLET, Y, PEREZ RUIXO, J, MA, Y, VON HOFF, D, KARASEK, P, OETTLE, H, VERVENNE, W. L, SZAWLOWSKI, A, SCHOFFSKI, P, POST, S, VERSLYPE, C, NEUMANN, H

“…To determine whether addition of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777; Johnson and Johnson Pharmaceutical Research and Development,…”
Get full text

Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy by Grothey, A., Tabernero, J., Arnold, D., De Gramont, A., Ducreux, M.P., O'Dwyer, P.J., Van Cutsem, E., Bosanac, I., Srock, S., Mancao, C., Gilberg, F., Winter, J., Schmoll, H.-J.

Get full text